Insulin is not a growth hormone. It is a metabolic hormone produced by the pancreas, and its primary job is regulating blood sugar. However, insulin does promote tissue growth in several ways, which is why the two get confused. Growth hormone (somatotropin) is a separate molecule made by the pituitary gland with a distinct set of functions. The relationship between insulin and growth is real, but it comes from overlap in their signaling pathways, not from being the same type of hormone.
How Insulin and Growth Hormone Differ
Insulin and human growth hormone (HGH) are produced by different glands, act through different receptors, and often push the body in opposite metabolic directions. Insulin lowers blood sugar by driving glucose into cells, suppressing the liver’s production of new glucose, and stopping the breakdown of stored glycogen. Growth hormone does nearly the reverse: it suppresses glucose uptake in fat tissue, stimulates the breakdown of stored fat by activating a fat-releasing enzyme, and increases glucose output from the liver and skeletal muscle.
When doctors prescribe growth hormone therapy, it commonly makes the body less responsive to insulin. That’s because growth hormone actively opposes insulin’s effects on muscle, liver, and fat tissue. The two hormones work as metabolic counterweights rather than teammates.
Why Insulin Gets Called a Growth Factor
Despite not being a growth hormone, insulin is genuinely anabolic, meaning it builds tissue. It stimulates fat cells to take up glucose and fatty acids, blocks the breakdown of stored fat, and drives new fatty acid production. Under sustained insulin stimulation, existing fat cells can swell to two to three times their original volume by packing in more stored fat. Insulin also promotes the formation of new fat cells by activating transcription factors involved in fat cell differentiation.
In muscle, insulin activates a signaling chain called the PI3K-Akt pathway, which is the same pathway that growth factors use to increase protein production and drive cell growth. This pathway controls cell size by ramping up protein synthesis at the translational level, effectively telling cells to build more structural protein. Both insulin and growth factors converge on this pathway, which is a major reason their effects overlap.
The confusion also has evolutionary roots. Insulin and insulin-like growth factor 1 (IGF-1) share significant structural similarity because they evolved from the same ancestral gene. Research on the primitive organism amphioxus found a hybrid molecule equally similar to both human insulin and IGF-1, suggesting that IGF (a true growth factor) split off from an ancestral insulin-type gene very early in vertebrate evolution. They’re molecular cousins. Insulin can even bind to the IGF-1 receptor, though with roughly 500-fold lower affinity than IGF-1 itself. At normal levels, this cross-binding is negligible. At very high levels, it starts to matter.
When Excess Insulin Actually Drives Growth
The strongest evidence that insulin promotes physical growth comes from clinical syndromes where the body produces far too much of it. Babies born with congenital hyperinsulinism, a condition of excessive insulin secretion, are typically large for their gestational age. The overgrowth happens because fetal insulin promotes growth partly through IGF-1 receptor signaling.
Several overgrowth syndromes are directly associated with hyperinsulinism. Beckwith-Wiedemann syndrome, the best studied, involves enlarged organs, asymmetric limb growth, and high birth weight. About half of affected newborns develop low blood sugar from the excess insulin. Sotos syndrome features macrosomia (unusually large body size) and accelerated bone maturation alongside excessive insulin production. Other conditions like Simpson-Golabi-Behmel syndrome and Perlman syndrome follow a similar pattern of too much insulin paired with abnormal physical overgrowth.
These syndromes demonstrate that while insulin isn’t classified as a growth hormone, flooding the body with it produces growth-promoting effects, particularly during fetal and early development when tissues are highly responsive.
Insulin Use in Bodybuilding
The growth-promoting properties of insulin haven’t gone unnoticed in athletic circles. Some bodybuilders inject short-acting insulin before or after workouts, pairing it with sugary foods or drinks to prevent dangerous blood sugar drops. The logic is that insulin’s ability to drive nutrients into muscle cells and activate protein-building pathways will amplify muscle growth, especially when stacked with anabolic steroids and growth hormone for potentially additive effects.
The risks are substantial. Severe hypoglycemia is the most immediate danger and can be fatal. Beyond that, research on bodybuilders who use insulin shows increased fat accumulation (the opposite of what most are aiming for), lower HDL (“good”) cholesterol, and elevated liver enzymes, which signal liver stress. Insulin use was specifically associated with altered fat metabolism in cell membranes and a skewed ratio of liver enzymes that suggests a distinct pattern of liver damage separate from steroid use alone.
The Insulin-IGF-1 Signaling Axis
Modern research increasingly treats insulin and IGF-1 as parts of a unified signaling system rather than completely separate hormones. The “insulin/IGF-1 axis” is now recognized as a central pathway in metabolic health, with shared downstream signaling through the PI3K/Akt pathway and the MAPK pathway. When this system malfunctions, the result is often insulin resistance, where cells stop responding normally to insulin’s signals.
Recent work has focused on proteins called insulin-like growth factor-binding proteins (IGFBPs) that regulate both sides of this axis. These binding proteins act as volume knobs, controlling how much IGF-1 is available to activate receptors. Elevated levels of one of these proteins, IGFBP-1, have been linked to poor recovery after stroke, suggesting these regulators influence outcomes well beyond simple glucose control. The tight integration of insulin and growth factor signaling explains why metabolic diseases like type 2 diabetes carry consequences that extend far beyond blood sugar, affecting tissue repair, inflammation, and body composition.
So while insulin is definitively not growth hormone, it sits at the center of a signaling network that overlaps heavily with growth pathways. The distinction matters for medical classification, but at the cellular level, the boundary between “metabolic hormone” and “growth signal” is blurrier than most textbooks suggest.